CureVac's reliance on lumpy, non-recurring milestone payments creates significant revenue volatility, as evidenced by a 91.4% year-over-year revenue decline in 2025Q2. While the company maintains a conservative debt-to-equity ratio of 0.06, the lack of a susta...
Price trend, volume and key moving averages
Trailing total returns as of 9/24/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2025Latest Nov 24, 2025 | -$0.10+41.2% vs -$0.17 | $573M vs — |
Q3 2025 Aug 15, 2025 | -$0.30-66.7% vs -$0.18 | $1M-62.7% vs $4M |
Q2 2025 May 20, 2025 | -$0.24-50.0% vs -$0.16 | $978,951-79.7% vs $5M |
Q2 2025 Apr 10, 2025 | -$0.15+31.8% vs -$0.22 | $15M+122.7% vs $7M |
Benchmark CVAC against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for CureVac N.V. (CVAC)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.66 | $1.05B | 6.47 | 895.54% | 30.3% | 26.73% | — | |
| $182.11 | $72.26B | -25.08 | -39.23% | -141.43% | -39.2% | — | |
| $98.46 | $24.73B | -19.18 | 0.2% | -64.02% | -9.13% | — | |
| $13.30 | $378.03M | -5.54 | -51.43% | -391.9% | -46.54% | — | |
| $12.33 | $1.38B | -3.24 | 16.92% | -672.16% | -57.79% | — | |
| $24.37 | $2.51B | -30.09 | 120.01% | -54.75% | -7.7% | — |
CureVac N.V. (CVAC) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Get notified when CVAC posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
CureVac N.V. (CVAC) stock FAQ — growth, dividends, profitability & financials explained
CureVac N.V. (CVAC) reported $510.5M in revenue for fiscal year 2024. This represents a 3866% increase from $12.9M in 2018.
CureVac N.V. (CVAC) grew revenue by 895.5% over the past year. This is strong growth.
Yes, CureVac N.V. (CVAC) is profitable, generating $193.6M in net income for fiscal year 2024 (30.3% net margin).
CureVac N.V. (CVAC) has a return on equity (ROE) of 26.7%. This is excellent, indicating efficient use of shareholder capital.
CureVac N.V. (CVAC) generated $196.1M in free cash flow for fiscal year 2024. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
